GlassScriptPhysician profile
Tamara Ann Lamb
NPI 1154446177
$1,132.11
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $42.41 · 2023: $41.41 · 2024: $26.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $189.82 | 2021 | |
| Abbvie INC. | $82.25 | 2022-2024 | |
| Foundation Medicine, INC. | $77.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $69.55 | 2021 | |
| Janssen Biotech, INC. | $52.84 | 2021-2022 | |
| Amgen INC. | $44.46 | 2021 | |
| Pfizer INC. | $42.04 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $41.05 | 2021 | |
| Seagen INC. | $32.51 | 2021 | |
| Myovant Sciences INC. | $29.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.11 | 2021 | |
| Taiho Oncology, INC. | $26.16 | 2021 | |
| Boston Scientific Corporation | $25.88 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $25.67 | 2021 | |
| Lilly USA, LLC | $25.00 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.79 | 2021 | |
| Gilead Sciences, INC. | $20.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.90 | 2021 | |
| Daiichi Sankyo INC. | $18.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.84 | 2021 | |
| Genentech USA, INC. | $17.40 | 2021 | |
| Array Biopharma INC | $17.34 | 2021 | |
| Aveo Pharmaceuticals, INC. | $16.94 | 2021 | |
| Eisai INC. | $16.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.84 | 2021 | |
| Glaxosmithkline, LLC. | $15.30 | 2021 | |
| Dova Pharmaceuticals | $14.52 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.49 | 2021 | |
| Karyopharm Therapeutics INC. | $14.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.48 | 2021 | |
| Morphosys, US INC. | $12.76 | 2021 | |
| Merck Sharp & Dohme LLC | $11.32 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.19 | 2021 | |
| Puma Biotechnology, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.